ArticleBMC geriatrics2025
Hospitalizations for cardiovascular events and risk for all cause and cardiovascular mortality in elderly patients with atrial fibrillation treated with oral anticoagulants: beyond preventing thromboembolism.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElderly patients with atrial fibrillation (AF) are at increased risk of death, despite oral anticoagulant (OAC) treatment. We estimated the risk of all cause and cardiovascular (CV) death associated with hospitalizations for cardiovascular events (CVEs).
settingRetrospective cohort study.
methodsOAC treated patients (≥ 75 years) (n = 2161) discharged from a Swedish cardiology clinic with AF or atrial flutter (AFL) as main diagnosis between 2010 and 2017, were followed up for 12 months. Hospitalizations for CVEs were recorded from the national patient registry and diagnoses combined in five groups: heart failure (HF); stroke/ transient ischemic attack (TIA)/systemic embolism (SE); acute myocardial infarction and peripheral artery disease; bleeding; and other CVEs. We estimated the risk, expressed as hazard ratio (HR) and 95% confidence interval (CI) for all-cause and CV death in each hospitalization group by time-varying Cox regression.
resultsDuring 12 months of follow up, 178 patients died and 92 were CV deaths. Overall, 391 (18.5%) patients experienced a total of 490 hospitalizations for CVEs. Hospitalizations for any CVEs associated with increased risk (from 3 to 17 folds) for all-cause mortality. Risk for CV mortality increased in patients hospitalized for HF within 90 days (HR and 95%CI) 33.64 (15.97-70.89), for stroke/TIA/SE 14.73 (7.60-28.58) and for other CVEs 8.98 (4.29-18.78).
conclusionsHospitalizations for CVEs in elderly AF/AFL OAC treated patients increased the risk for all cause and CV mortality within 12 months from admission for AF/AFL. Hospitalization for HF bared the highest risk, but the residual stroke/TIA/SE risk was noteworthy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.